Alvesco and Hyperventilation - a phase IV clinical study of FDA data

Summary:

Hyperventilation is reported as a side effect among people who take Alvesco (ciclesonide), especially for people who are female, 30-39 old, also take Singulair, and have Urticaria.

The phase IV clinical study analyzes which people have Hyperventilation when taking Alvesco. It is created by eHealthMe based on reports of 13,009 people who have side effects when taking Alvesco from the FDA, and is updated regularly.

What is Alvesco?

Alvesco has active ingredients of ciclesonide. It is often used in asthma. eHealthMe is studying from 13,134 Alvesco users. Check the latest studies of Alvesco.

What is Hyperventilation?

Hyperventilation is found to be associated with 704 drugs and 1,444 conditions by eHealthMe. Check the latest studies of Hyperventilation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

13,009 people reported to have side effects when taking Alvesco.
Among them, 54 people (0.42%) have Hyperventilation.

Among these 54 people:

What is the gender of people who have Hyperventilation when taking Alvesco? *

female: 96 %
male: 4 %

What is the age of people who have Hyperventilation when taking Alvesco? *

What are other drugs people take besides Alvesco? *

What are other side effects people have besides Hyperventilation? *

Conjunctivitis (pink eye): 51 people, 94.44%
Nausea (feeling of having an urge to vomit): 51 people, 94.44%
Dizziness: 51 people, 94.44%
Wheezing (a high-pitched whistling sound made while you breath): 50 people, 92.59%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 50 people, 92.59%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 50 people, 92.59%
Cough: 50 people, 92.59%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 50 people, 92.59%
Chest Pain: 50 people, 92.59%
Urticaria (rash of round, red welts on the skin that itch intensely): 49 people, 90.74%

What are the existing conditions these people have? *

Urticaria (rash of round, red welts on the skin that itch intensely): 29 people, 53.70%
Hypersensitivity: 11 people, 20.37%
Pain: 8 people, 14.81%
Multiple Allergies (allergy to multiple agents): 5 people, 9.26%
Osteoporosis (bones weak and more likely to break): 1 person, 1.85%
Migraine (headache): 1 person, 1.85%
Immunodeficiency Common Variable: 1 person, 1.85%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 1.85%
Hormone Level Abnormal: 1 person, 1.85%
High Blood Cholesterol: 1 person, 1.85%

* Approximation only. Some reports may have incomplete information.

Do you take Alvesco and have Hyperventilation?

- Check whether Hyperventilation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Alvesco:

Alvesco (13,134 reports)

Browse all side effects of Alvesco:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperventilation:

Hyperventilation (704 drugs)

Browse all the conditions that are associated with Hyperventilation:

Hyperventilation (1,444 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ciclesonide (the active ingredients of Alvesco) and Alvesco (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.